NKG2D-based CAR T-cell treatment (i.v. or i.t.) confers a survival benefit in syngeneic orthotopic glioma-bearing mice. Surviving mice were protected long-term against tumor rechallenge. CAR-T cells migrated to the tumor site in the brain after systemic administration. This evidence concerns the gene KLRK1 and neoplasm.